Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

What Administration Sites Need to Know

Monoclonal antibodies (or mAbs) are a critical tool in fighting the COVID-19 pandemic, and the U.S. Department of Health and Human Services (HHS) is committed to fair and equitable access to these important products.  A surge in the Delta variant coupled with low vaccination rates in certain areas of the country contributed to an increase in COVID-19 over the July-August timeframe.

As a result, the HHS Office of the Assistant Secretary for Preparedness and Response (HHS/ASPR) implemented a State and Territorial-Coordinated Distribution System for mAbs on Sep 13, 2021, similar to one that was in place from November 2020 to February 2021.  Currently, REGEN-COV and bamlanivimab/etesevimab are being distributed through this state/territory coordinated distribution system. 


announcement icon map icon hospital icon computer icon

Step 1
HHS/ASPR
announces distribution
quantities each
Tuesday

Step 2
State/territorial
health departments
allocate product
administration sites

Step 3
Administration
sites dispense
mAbs to
eligible patients

Step 4
Administration sites
report on product utilization
and stock on hand on
Wednesdays by 11:59 PM ET

View Distribution
Tables >>

About Receiving
Product >>
Patient
Eligibility >>
Reporting
Requirements >>


question and answer Icon

Questions?

If you have questions about the new state/territory coordinated distribution system, check out our frequently asked questions section.                

View the FAQs >>

  • This page last reviewed: September 24, 2021